Patients' perception, and adherence to treatment with biosimilar adalimumab in psoriasis

Dermatol Ther. 2022 Feb;35(2):e15227. doi: 10.1111/dth.15227. Epub 2021 Dec 1.

Authors

Sahar Dadkhahfar¹, Laya Ohadi¹, Yasaman Rahimi¹, Reza M Robati^{1

2}, Marjan Shekarabi³, Omid Zargari¹, Mohammad Shahidi-Dadras¹

Affiliations

¹ Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
² Department of Dermatology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
³ Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.

PMID: 34822212
DOI: 10.1111/dth.15227

No abstract available

Publication types

Letter

MeSH terms

Adalimumab / therapeutic use
Biosimilar Pharmaceuticals* / therapeutic use
Humans
Perception
Psoriasis* / drug therapy
Severity of Illness Index

Substances

Biosimilar Pharmaceuticals
Adalimumab